A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens.

Purpose: To investigate the feasibility of intrapatient dose-escalation methodology for dose-ranging studies of conventional cytotoxics in combination.

Patients And Methods: Case records were identified for patients with ovarian cancer treated first-line with either single-agent carboplatin or carboplatin and paclitaxel in combination and routinely subjected to a 10% dose escalation in carboplatin at each cycle, towards a target day-22 neutrophil count in the range 1.0-1.